Determinantes de adherencia al tratamiento antihipertensivo de adultos ≥ 35 años de edad
Palavras-chave:
Hipertensión, Cumplimiento de la medicación, Agentes antihipertensivos, Comorbilidad, Adulto, Factores epidemiológicosResumo
Resumen
Introducción: La hipertensión es una condición prevalente y un factor de riesgo que conduce a morbi-mortalidad alrededor del mundo. El objetivo de este estudio es establecer los determinantes de adherencia al tratamiento hipertensivo en adultos sobre 35 años de edad de Pasto, Colombia. Método: Un estudio transversal fue llevado a cabo para establecer los determinantes de adherencia a la terapia farmacológica antihipertensiva en 128 adultos del “Centro de Salud Lorenzo de Aldana”. La evaluación de la adherencia fue hecha a través del test de Morisky-Green versión en Español. Un análisis descriptivo fue usado para variables demográficas y una regresión logística fue ejecutada para calcular un resultado dicotómico para los determinantes de adherencia. Resultados: La muestra de estudio consistió en 40 (31,3%) hombres y 88 (68,8%) mujeres pacientes hipertensos. El porcentaje de adherencia a la medicación fue 41.4%. Los pacientes hombres tenían mayor probabilidad de estar adheridos al tratamiento hipertensivo cuando ellos usaban más de un medicamento antihipertensivo, tal como inhibidores de la enzima convertidora de angiotensina, bloqueadores de los canales de calcio y diuréticos (OR:4,16; IC al 95%:0,34-5,61), ellos estaban casados (OR:2,97; IC al 95%: 0,72- 11,73) y ellos estaban hospitalizados (OR:1,92; IC al 95%: 0,11- 33,30). Sin embargo, las pacientes mujeres cuando ellas no tenían comorbilidad (OR:4,27; IC al 95%: 0,81-22,49), ellas estaban entre 35 y 45 años (OR:4.0; IC al 95%:0,39-40,05) y ellas eran solteras (OR:2,56; IC al 95%:1,03-6,38) fueron más adherentes. Conclusiones: Estos hallazgos sugieren que los determinantes de la adherencia a tratamientos antihipertensivos podrían depender del género.
Abstract
Introduction: Hypertension is a prevalent condition and a risk factor for morbidity and mortality around the world. The aim of this study is to establish the adherence determinants to antihypertensive treatment in adults over 35 from Pasto, Colombia. Methods: A cross-sectional study was conducted to establish the adherence determinants to antihypertensive pharmacotherapy in 128 adults at “Centro de Salud Lorenzo de Aldana”. The adherence evaluation was made through the Morisky-Green test in its Spanish version. A descriptive analysis was used for demographic variables, and a logistic regression was performed to calculate a dichotomous outcome by adherence determinants. Results: The study sample consisted of 40 (31.3%) men and 88 (68.8%) women who are hypertensive patients. The percentage of adherence to medication was 41.4%. Male patients were more likely to be adherent to hypertensive treatment when they used more than one antihypertensive drugs such as angiotensin converting enzyme inhibitors, calcium channel blockers and diuretics (OR:4.16; 95% CI:0.34, 5.61), when they were married (OR:2.97; 95% CI:0.72, 11.73), and when they were hospitalized (OR:1.92; 95 % CI:0.11, 33.30). However, female patients were adherent when they did not have comorbidity (OR: 4.27; 95% CI: 0.81, 22.49), when they were 35 to 45 years old (OR:4.0; 95% CI:0.39, 40.05), and when they were single (OR:2.56; 95% CI:1.03, 6.38). Conclusions: These findings suggest that adherence determinants to antihypertensive treatment may depend on gender.
Downloads
##plugins.generic.paperbuzz.metrics##
Referências
2. Egan B, Zhao Y, Axon R. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA. 2010;303:2043- 2050.
3. Tian S, Dong G, Wang D, Liu M, Lin Q, Meng X, et al. Factors associated with prevalence, awareness, treatment and control of hypertension in urban adults from 33 communities in China: the
CHPSNE Study. Hypertens Res. 2011. [en prensa].
4. Barquera S, Campos I, Hernández L, Villalpando S, Rodríguez C, Durazo R, et al. Hypertension in Mexican adults: results from the National Health and Nutrition Survey 2006. SaludPublica Mex.
2010;52(Suppl 1):S63-71.
5. Lessa I. Systemic arterial hypertension in Brazil: temporal trends. Cad Saude Publica. 2010;26:1470.
6. Almeida F, Konigsfeld H, Machado L, Canadas A, Issa E, Giordano R, Cadaval R. Assessment of social and economic influences on blood pressure of adolescents in public and private schools: an epidemiological study. J Bras Nefrol. 2011;33:142-149.
7. Organización Panamericana de la Salud (PAHO). Ministerio de la Protección Social de Colombia. Indicadores Básicos 2008. [Online]. Citado en 2008. [fecha de acceso: 27 de Julio de 2011]. Disponible en URL: http://new.paho.org/col/index.php?option=com_content&task=view&id=25&Itemid=135
8. Instituto Departamental de Nariño. Indicadores Básicos de Salud. Departamento de Nariño –2009. [Online]. Citado en 2011. [fecha de acceso: 13 de Agosto de 2011]. Disponible en URL:
http://www.idsn.gov.co/
9. Sandhu J, Berri A, Gupta D, Arya M, Singh R, Sandhu P. Essential Hypertension- Primary Prevention.
JIACM. 2004;5:306-309.
10. Dhaneshwar S, Sharma M, Patel V, Desai U, Bhojak J. Prodrug Strategies for Antihypertensives.
Curr Top Med Chem. 2011;11:2299-2317.
11. Neff K, Nawarskas J. Hydrochlorothiazide versus chlorthalidone in the management of hypertension. Cardiol Rev. 2010;18:51-56.
12. Reidenberg M. Drug discontinuation effects are part of the pharmacology of a drug. J Pharmacol
Exp Ther. 2011;339:324-328.
13. Organización Panamericana de la Salud (PAHO). Adherencia a los tratamientos a largo plazo.
Pruebas para la acción. [Online]. Citado en 2004. [fecha de acceso: 21 de Julio de 2011] Disponible
en URL: http://www.paho.org/spanish/ad/dpc/nc/nc-adherencia.htm
14. Sabaté E. Adherence to long-term therapies: evidence for action. Geneva, Switzerland: WHO;
2003.
15. Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood
Pressure. The sixth report of the Joint National Committee on prevention, detection, evaluation
and treatment of high blood pressure. Arch Intern Med. 1997;157:2413-2446.
16. Kauric Z. Predictors of non adherence with blood pressure regimens in hemodialysis. Patient
Prefer Adherence. 2013;7:973-980.
17. Mayor S. Non-adherence to medication increases stroke risk in patients with high blood pressure.
BMJ. 2013;347:f4586.
18. Tuesca R, Guallar P, Banegas J, Graciani A. Determinantes del cumplimiento terapéutico en personas
mayores de 60 años en España. Gac Sanit. 2006;20:220-227.
19. Ross S, Walker A, MacLeod M. Patient compliance in hypertension: role of illness perceptions
and treatment beliefs. J HumHypertens. 2004;18:607-613.
20. Fernández S, López M, Comas A, García E, Cueto A. Categorización de factores psicosociales asociados al cumplimiento farmacológico antihipertensivo. Psicothema. 2003;15:82-87.
21. Arce L, Monge J. Género y niveles de adherencia al tratamiento antihipertensivo en el personal de
la Universidad Estatal a Distancia de Costa Rica. Cuadernos de Investigación UNED. 2009;1:163-170.
22. Crespo N, Rubio V, Casado M, Sánchez J, Campos C. Factores moduladores de la adherencia farmacológica en hipertensión arterial. Hipertensión. 2000;17:4-8.
23. Palop V, Martínez I. Información terapéutica del Sistema Nacional de Salud. InfTerSistNacSalud. 2004;28:113-120.
24. Chen L, Shi Q, Ding R, Hu D. The prevalence, awareness, and control of hypertension in Xianghe county of Hebei province. Zhonghua NeiKeZaZhi. 2013;52:185-187. [Article in
Chinese].
25. National Institute of Health. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure.JAMA. 2003;289:2560-2572.
26. Morisky D, Green L, Levine D. Concurrent and predictive validity of a self-reported measure of medication adherence. MedCare. 1986;24:67-74.
27. Carhuallanqui R, Diestra G, Tang J, Málaga G. Adherencia al tratamiento farmacológico en pacientes hipertensos atendidos en un hospital general. Rev Med Hered. 2010;21:197-201.
28. Warren J, Seymour R. Prevalence rates of hypertension self-care activities among African Americans. J Natl Med Assoc. 2011;103:503-512.
29. Grosso G, Raciti T, Marventano S, Romeo I, Mistretta A. Adherence to antihypertensive and lipid-lowering medications: a problem of public health, not yet resolved. Ann Ig. 2011;23:173-184.
30. Org E, Veldre G, Viigimaa M, Juhanson P, Putku M, Rosenberg M, et al. HYPEST study: profile of hypertensive patients in Estonia. BMC CardiovascDisord. 2011;11:55.
31. Puavilai W, Laorugpongse D, Prompongsa S, Sutheerapatranont S, Siriwiwattnakul N, Muthapongthavorn N, et al. Prevalence and some important risk factors of hypertension in Ban Paew District, second report. J Med Assoc Thai. 2011;94:1069-1076.
32. Shishani K, Dajani R, Khader Y. Hypertension Risk Assessment in the Largest Ethnic Groups in
Jordan. J Immigr Minor Health. 2013;15:43-48.
33. Eiser A, FACP, Ellis G. Viewpoint: Cultural Competence and the African American Experience with Health Care: The Case for Specific Content in Cross-Cultural Education. Acad Med.
2007;82:176–183.
34. Cooper L, Roter D, Carson K, Bone L, Larson S, Miller E, et al. A randomized trial to improve patient-centered care and hypertension control in underserved primary care patients. J Gen Intern Med. 2011;26:1297-1304.
35. Catić T, Begović B. Outpatient antihypertensive drug utilization in Canton Sarajevo during five
years period (2004-2008) and adherence to treatment guidelines assessment. Bosn J Basic MedSci. 2011;11:97-102.
36. Ingaramo R, Vita N, Bendersky M, Arnolt M, Bellido C, Piskorz D, et al. Estudio Nacional Sobre Adherencia al Tratamiento (ENSAT). Rev Fed Arg Cardiol. 2005;34:104-111.
37. Fretheim A. Back to thiazide-diuretics for hypertension: reflections after a decade of irrational prescribing. BMC Family Practice.2003, 4:19-22.
38. Centers for Disease Control and Prevention. Morbidity and Mortality Weekly Report. Vital Signs: Prevalence, Treatment, and Control of Hypertension— United States, 1999-2002 and 2005-2008. 2011;305:1531-1534.
39. Goma F, Nzala S, Babaniyi O, Songolo P, Zyaambo C, Rudatsikira E, Siziya S, Muula AS. Prevalence of hypertension and its correlates in Lusaka urban district of Zambia: a population based survey. Int
Arch Med. 2011;4:34.
40. Hsu L, Sin K, Rajasoorya C, Chew L. Hypertension in the Young Adult – Come feel the pulse. Singapore Med J. 2000;41: 235-238.
41. Davidson K, Jonas B, Dixon K, Markovitz J. Do Depression Symptoms Predict Early Hypertension Incidence in Young Adults in the CARDIA Study? Arch Intern Med. 2000;160:1495-1500.
42. Krousel M, Joyce C, Holt E, Muntner P, Webber LS, Morisky D, et al. Predictors of decline in medication adherence: Results from the cohort study of medication adherence among older adults. Hypertension. 2011;58:804-810.
43. Macia E, Duboz P, Gueye L. Prevalence, awareness, treatment and control of hypertension among adults 50 years and older in Dakar, Senegal. Cardiovasc J Afr. 2012;23:265-269.
44. Marcus E. The silent epidemic — The Health Effects of Illiteracy. N Engl J Med. 2006; 355:339-341.
45. Fletschner D, Anderson C, Cullen A. Are women as likely to take risks and compete? Behavioural findings from central Vietnam. J Dev Stud. 2010;46:1459-1479.
46. Petrella R, Campbell N. Awareness and misconception of hypertension in Canada: results of a national survey. Can J Cardiol. 2005;15(21):589-593.
47. Khan N, Hemmelgarn B, Herman R, Bell C, Mahon J, Leiter L, Canadian Hypertension Education Program. The 2009 Canadian Hypertension Education Program recommendations for the
management of hypertension: Part 2--therapy. Can J Cardiol. 2009;25:287-298.
48. Al Khaja K, Sequeira R, Damanhori A. Pharmacotherapy and blood pressure control in elderly hypertensives in a primary care setting in Bahrain. Aging Clin Exp Res. 2004;16:319-325.
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Copyright (c) 2015 Universidad y Salud
Este trabalho está licenciado sob uma licença Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
